Albumin bound paclitaxel for the treatment of retreatment advanced non-small-cell lung cancer
10.3760/cma.j.issn.1006-9801.2016.05.010
- VernacularTitle:白蛋白结合型紫杉醇治疗复治晚期非小细胞肺癌临床观察
- Author:
Lin LI
;
Ping ZHANG
;
Hui WANG
;
Zijin ZHANG
;
Xiaonan WU
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Albumin bound paclitaxel;
Antineoplastic combined chemotherapy protocols;
Retreatment
- From:
Cancer Research and Clinic
2016;28(5):325-327
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of albumin bound paclitaxel in the treatment of retreatment advanced non-small-cell lung cancer (NSCLC).Methods Retreatment NSCLC patients failed from first line regimen or beyond were treated with albumin bound paclitaxel weekly by intravenous dose of 130 mg/m2 on day 1 and day 8,with a 21-day cycle.Efficacy was evaluated every two cycles and side effects were observed during each cycle.Results None of 69 patients achieved complete remission (CR),15 patients (21.7 ％) achieved partial remission (PR),and 23 patients (33.4 ％) achieved stable disease (SD).Objective response rate (ORR) was 21.7 ％,disease control rate (DCR) was 55.1％,and progress free survival (PFS) time was 3.8 months.Efficacy was not correlated with gender,age,histology and lines of previous treatment (all P ＞ 0.05).Main adverse reactions included neutropenia,alopccia and neurotoxicity,which were all tolerable.Conclusion Weekly albumin bound paclitaxel is effective and well tolerated in the treatment of retreatment advanced NSCLC,which can be considered as the second line or beyond regimen.
